Dr. Reddy’s acquires GSK's US penicillin facility and products

NewsGuard 100/100 Score
Mar 30 2011

Dr. Reddy's Laboratories (NYSE:RDY) today announced the completion of the acquisition of GlaxoSmithKline's (GSK) United States oral penicillin facility and product portfolio pursuant to the agreement signed and announced by the companies on Nov 23, 2010. As a result of the acquisition, Dr. Reddy's assumes the ownership of the penicillin manufacturing site in Bristol, Tennessee, United States, and rights for the Augmentin® and Amoxil® brands in the United States. GSK will retain the existing rights for these brands outside the United States. Further financial terms and conditions of the transaction are not being disclosed.

Source:

Dr. Reddy's Laboratories

Posted in: Business / Finance | Pharmaceutical News

Tags: , , , ,

Comments (0)

Suggested Reading

High-fiber diets may help control the adverse effects of antibiotic treatments on beneficial gut microbiota
New study reveals effective strategies against drug resistance in hospital-acquired pneumonia treatment
Rising antimicrobial resistance in STIs: A call for global action
Is the new bivalent COVID-19 vaccine the booster we've been waiting for?
Neonatal ICU mystery: Unraveling the secrets of the prevalent Staphylococcus strain
Broad-spectrum antibiotics linked to higher sepsis risk in neonates
Surge in syphilis cases leads some providers to ration penicillin
Rapid rise in syphilis hits Native Americans hardest

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Alarming rise in antibiotic-resistant urogenital infections in Greece, study shows escalating resistance trends